AlzeCure Pharma AB (FRA:AC6) ROC (Joel Greenblatt) %: -2,219.89% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AC6 AlzeCure Pharma AB FRA:AC6
35 GF Score
Price €0.52
! 1 Warning Sign
View Full Analysis

What is AlzeCure Pharma AB ROC (Joel Greenblatt) %?

AlzeCure Pharma AB FRA:AC6 -3.37% 35 ROC (Joel Greenblatt) % is -2,219.89% as of Mar. 2026. GuruFocus rates FRA:AC6 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,323 Biotechnology companies, AlzeCure Pharma AB ranks worse than 76.95% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. AlzeCure Pharma AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2,219.89%.

The historical rank and industry rank for AlzeCure Pharma AB's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:AC6' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8556.14   Med: -4288.29   Max: -590.41
Current: -2358.99

During the past 9 years, AlzeCure Pharma AB's highest ROC (Joel Greenblatt) % was -590.41%. The lowest was -8556.14%. And the median was -4288.29%.

FRA:AC6's ROC (Joel Greenblatt) % is ranked worse than
76.95% of 1323 companies
in the Biotechnology industry
Industry Median: -296.6 vs FRA:AC6: -2358.99

AlzeCure Pharma AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 33.80% per year.


AlzeCure Pharma AB  (FRA:AC6) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


AlzeCure Pharma AB ROC (Joel Greenblatt) % Related Terms


AlzeCure Pharma AB ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for AlzeCure Pharma AB's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AlzeCure Pharma AB ROC (Joel Greenblatt) % Chart

AlzeCure Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -4,603.65 -4,758.14 -1,005.14 -581.30 -1,040.86

AlzeCure Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,533.19 -26,192.59 -1,772.13 -1,688.31 -2,219.89

FRA:AC6 vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, AlzeCure Pharma AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AlzeCure Pharma AB ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AlzeCure Pharma AB's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where AlzeCure Pharma AB's ROC (Joel Greenblatt) % falls into.


FRA:AC6
35GF Score
AlzeCure Pharma AB FRA:AC6
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AlzeCure Pharma AB ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.0090000000000003) - (0.448 + 0 + 1.717)
=-2.156

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.607 + 0 + 1.926)
=-2.533

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of AlzeCure Pharma AB for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.036/( ( (0.373 + max(-2.156, 0)) + (0.351 + max(-2.533, 0)) )/ 2 )
=-8.036/( ( 0.373 + 0.351 )/ 2 )
=-8.036/0.362
=-2,219.89 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -2,219.89% mean?
AlzeCure Pharma AB (FRA:AC6) has a ROC (Joel Greenblatt) % of -2,219.89% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on AlzeCure Pharma AB and its competitors. According to the industry distribution chart, AlzeCure Pharma AB ranks #1018 out of 1323 companies in the Biotechnology industry, placing it in the top 76.9%.
Is AlzeCure Pharma AB's ROC (Joel Greenblatt) % too high?
AlzeCure Pharma AB's current ROC (Joel Greenblatt) % is -2,219.89%. Based on the distribution chart, AlzeCure Pharma AB ranks #1018 out of 1323 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AlzeCure Pharma AB has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does AlzeCure Pharma AB's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AlzeCure Pharma AB ranks #1018 out of 1323 companies for ROC (Joel Greenblatt) %. This places AlzeCure Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on AlzeCure Pharma AB and its competitors. AlzeCure Pharma AB's current ROC (Joel Greenblatt) % is -2,219.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AlzeCure Pharma AB stock overvalued right now?
AlzeCure Pharma AB (FRA:AC6) has a current ROC (Joel Greenblatt) % of -2,219.89%. The current ROC (Joel Greenblatt) % is -2,219.89%. AlzeCure Pharma AB's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For AlzeCure Pharma AB (FRA:AC6), the current ROC (Joel Greenblatt) % is -2,219.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AlzeCure Pharma AB Business Description

Other Exchanges ALZCUR:Sweden
Address Halsovagen 7, Huddinge, SWE, SE 141 57
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
35GF Score

Get the complete analysis for FRA:AC6

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.52
Price